San Diego
,
USA
7 - 10 December 2024
American Society of Hematology, 2024 (ASH)
Presentation schedule and materials
Friday, 06 December 2024
15:00
- 18:00
PST
Symposium
Cases and Conversations: The rational for utilizing non-factor replacement therapies in hemophilia care
Steven Lentz, MD, PhD
;
Stacy E. Croteau, MD, MMS
;
Alice Ma, MD FACP
MATERIALS AVAILABLE
Coming soon
Saturday, 07 December 2024
15:00
- 15:30
PST
179
ORAL PRESENTATION
Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 Weeks
Sophia Delicou1; Fuad El Rassi2; Biree Andemariam3; Miguel R. Abboud4; Julie Kanter5; Marilyn J. Telen6; Jessie Githanga7; Adlette Inati8; Ibrahim Idris9; Sunil Navani10; Eric Wu11; Andrew Eisenberger12
MATERIALS AVAILABLE
17:30
- 19:30
PST
1212
POSTER
Mim8 prophylaxis beyond bleeding: Investigating multifaceted, patient-reported outcomes for hemophilia A in the FRONTIER2 study
Cedric Hermans1; Cihan Ay2; Carmen Escuriola3; Peter Kampmann4; Rikke Medom Meldgaard5; Ilgiz Rakhmatullin5; Ciprian Tomuleasa6; Lize Fie Ditteke van Vulpen7; Michael Wang8; Irena Woznica Karczmarz9; Sophie Susen10
MATERIALS AVAILABLE
17:30
- 19:30
PST
1135
POSTER
Characterizing people with sickle cell disease who share attitudes regarding clinical trial participation: Findings from the global LISTEN survey
Johnny Mahlangu1; John James2; Biree Andemariam3; John Waller4; Samar Al-Behaisi4; Gareth Morrell5; Raffaella Colombatti6; Cassandra Trimnell7
MATERIALS AVAILABLE
17:30
- 19:30
PST
1137
POSTER
How people with sickle cell disease rate motivators is associated with the likelihood of wanting to participate in a clinical trial: Findings from the global LISTEN survey
Biree Andemariam1; Johnny Mahlangu2; Raffaella Colombatti3; John Waller4; Samar Al-Behaisi4; Gareth Morrell5; John James6
MATERIALS AVAILABLE
17:30
- 19:30
PST
1124
POSTER
Large scale analysis of the real-world association between fetal hemoglobin and vaso-occlusive crises in sickle cell disease
Peter Bruun-Rasmussen1; Elena Dudukina1; Lars Peter Korsholm1; Julie Derving Karsbøl1; Inga Hegemann1; Maarten Jan Wensink1
MATERIALS AVAILABLE
17:30
- 19:30
PST
1139
POSTER
Motivators and barriers for people with sickle cell disease participating in clinical trials: United States findings from the LISTEN survey
Biree Andemariam1; Adam Wufsus2; Erik Hecht2; Cassandra Trimnell3
MATERIALS AVAILABLE
17:30
- 19:30
PST
2318
POSTER
Physical and psychological burden on people with hemophilia: Global real-world data
Giancarlo Castaman1; Cléa Percier2; Naveen Shridhar3; Neil Reynolds4; Olivera Rajkovic-Hooley4; Thom Dewar4; Victor Jiménez-Yuste5
MATERIALS AVAILABLE
17:30
- 19:30
PST
900
POSTER
Noninvasive, accessible, smartphone app for at home hemoglobin monitoring in sickle cell disease
Rob Mannino1; Kunjan Rana2; Wilbur Lam3,4; Inga Hegemann5,6; Janne Toftegaard Madsen2; Erika Tyburski1
MATERIALS AVAILABLE
Sunday, 08 December 2024
18:00
- 20:00
PST
2461
POSTER
Etavopivat increases arterial hemoglobin-oxygen saturation during moderate and severe hypoxia: A mechanistic phase 1 trial in healthy volunteers
Chad C. Wiggins1; Kevin L. Webb1; Jacob L. Gasner2; Wyatt W. Pruter1; Sunil Navani3; Marcus A. Carden4; Michael J. Joyner1
MATERIALS AVAILABLE
18:00
- 20:00
PST
2585
POSTER
Unmet needs of patients with hemophilia A/B with or without inhibitors: Real-world end-of-study results from the explorer6 non-interventional study
Wheeler AP1; Abraham A2; Barnes C3; Brown Frandsen R4; Hampton K5; Lopez-Jaime FJ6; Martins Mazini Tavares C4; Nogami K7; Windyga J8; Castaman G9
MATERIALS AVAILABLE
Monday, 09 December 2024
10:30
- 12:00
PST
715
ORAL PRESENTATION
Annualized bleeding rates in patients with hemophilia A or B and inhibitors with and without target joints at baseline: Results from the concizumab phase 3 explorer7 study
Shapiro A1; Apte S2; Boban A3; Brown Frandsen R4; Linari S5; Mahlangu J6; Martins Mazini Tavares C4; Matsushita T7; Nekkal S8; Sathar J9; Chan AKC10
MATERIALS AVAILABLE
11:15
- 11:30
PST
718
ORAL PRESENTATION
Safety and efficacy of Mim8 prophylaxis administered once every two weeks for patients with hemophilia A with or without inhibitors: Interim analysis of the FRONTIER4 open-label extension study
Tadashi Matsushita1; Pratima Chowdary2; Atanas Banchev3; Kaan Kavakli4; Johanna A. Kremer Hovinga5; Jerzy Windyga6; Victor Jiménez-Yuste7; Julien Bovet8; Llenalia María García Fernández9; Guy Young10
MATERIALS AVAILABLE
18:00
- 20:00
PST
5077
POSTER
Burden of treatment on people with hemophilia: Global real-world data
Victor Jiménez-Yuste1; Cléa Percier2; Naveen Shridhar3; Neil Reynolds4; Olivera Rajkovic-Hooley4; Thom Dewar4; Giancarlo Castaman5
MATERIALS AVAILABLE
Keywords